{
    "ticker": "PRAX",
    "name": "Praxis Precision Medicines, Inc.",
    "description": "Praxis Precision Medicines, Inc. is a biopharmaceutical company focused on developing innovative therapies for patients suffering from central nervous system (CNS) disorders. Founded in 2015, Praxis is dedicated to addressing the significant unmet needs in the treatment of neurological diseases through a precision medicine approach. The company utilizes its proprietary drug discovery platform to identify and develop molecules that target specific mechanisms of action in the brain, aiming to provide more effective and safer treatments. Praxis is particularly focused on conditions like epilepsy, anxiety, and mood disorders, with several clinical-stage programs in its pipeline. The company has made significant strides in advancing its lead candidate, which is currently undergoing clinical trials and shows promise in treating drug-resistant epilepsy. Praxis is committed to transforming the lives of patients through scientific innovation and a patient-centric approach, working closely with the medical community to ensure that its therapies are aligned with patient needs and treatment goals.",
    "industry": [
        "Biopharmaceuticals",
        "Healthcare"
    ],
    "headquarters": "Boston, Massachusetts, USA",
    "founded": "2015",
    "website": "https://www.praxismedicines.com",
    "ceo": "Marcio Souza",
    "social_media": {
        "twitter": "https://twitter.com/PraxisMeds",
        "linkedin": "https://www.linkedin.com/company/praxis-precision-medicines/"
    },
    "investor_relations": "https://investors.praxismedicines.com",
    "key_executives": [
        {
            "name": "Marcio Souza",
            "position": "CEO"
        },
        {
            "name": "David A. S. Shapiro",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Clinical Programs",
            "products": [
                "PRAX-944",
                "PRAX-555"
            ]
        }
    ],
    "seo": {
        "meta_title": "Praxis Precision Medicines, Inc. | Innovative CNS Therapies",
        "meta_description": "Explore Praxis Precision Medicines, Inc., a leader in developing innovative therapies for CNS disorders. Learn about our commitment to patient-centric treatments.",
        "keywords": [
            "Praxis Precision Medicines",
            "CNS Disorders",
            "Biopharmaceuticals",
            "Epilepsy Treatment",
            "Neurological Diseases",
            "Precision Medicine"
        ]
    },
    "faq": [
        {
            "question": "What is Praxis Precision Medicines known for?",
            "answer": "Praxis Precision Medicines is known for developing innovative therapies for central nervous system disorders."
        },
        {
            "question": "Who is the CEO of Praxis Precision Medicines?",
            "answer": "Marcio Souza is the CEO of Praxis Precision Medicines, Inc."
        },
        {
            "question": "Where is Praxis headquartered?",
            "answer": "Praxis is headquartered in Boston, Massachusetts, USA."
        },
        {
            "question": "What are Praxis's main products?",
            "answer": "Praxis's main products include PRAX-944 and PRAX-555, which are in clinical development for treating CNS disorders."
        },
        {
            "question": "When was Praxis founded?",
            "answer": "Praxis was founded in 2015."
        }
    ],
    "competitors": [
        "AXSM",
        "SAGE",
        "HRTX",
        "PTGX"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "BMY",
        "JNJ"
    ]
}